About RSV Prefusion F (Pre-F0) Glycoprotein

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants, young children, older adults, and immunocompromised individuals. The RSV fusion (F) glycoprotein is an essential viral surface protein that mediates fusion of the viral envelope with host-cell membranes and enables viral entry into susceptible cells. Because of its critical role in infection, the F protein has become the primary target for RSV vaccine development, neutralizing antibody discovery, and antiviral therapeutic research.

The RSV F protein exists in two major conformational states: a metastable prefusion (Pre-F) form and a stable postfusion (Post-F) form. The prefusion conformation contains highly potent neutralizing epitopes that are absent or altered after conversion to the postfusion state. As a result, the prefusion F protein has emerged as the preferred antigen for modern RSV vaccines and immunological studies.

eEnzyme's recombinant RSV Prefusion F (Pre-F0) Glycoprotein is expressed in mammalian cells and is suitable for vaccine research, neutralizing antibody screening, receptor-binding studies, structural biology investigations, and immunological assay development. The protein can be utilized to support studies of viral entry mechanisms, epitope mapping, immune response characterization, and next-generation RSV vaccine design.

Applications of RSV Prefusion F Glycoprotein

• RSV vaccine development and evaluation
• Neutralizing antibody discovery and characterization
• Viral entry and membrane fusion studies
• Structural biology and epitope mapping
• ELISA, Western blot, and immunological assays
• Antiviral therapeutic research

Biological Significance of RSV Prefusion F

The RSV prefusion F protein is the major target of protective neutralizing antibodies generated during natural infection and vaccination. Antibodies directed against prefusion-specific epitopes can block conformational changes required for membrane fusion and viral entry, thereby preventing infection. Because of its ability to elicit potent neutralizing responses, the prefusion F antigen forms the basis of multiple licensed and investigational RSV vaccines and remains a central focus of RSV prevention and therapeutic research.